Balancing cost:benefit in ‘well-treated’ malignancies

30 April 2018

Oncologists and pharmaceutical companies are increasingly discussing the cost:benefit ratio of cancer treatments. It is a topic that is under the microscope, particularly now, with the advent of immunotherapies. In our latest whitepaper, Jeremy Smith (Associate Director in the Oncology Research Group at THE PLANNING SHOP) discusses the cost:benefit ratio of the rising prices of new oncology treatments and how the pharmaceutical industry and regulators can adequately address them while still promoting R&D.